

Jason Tay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5253063/publications.pdf>

Version: 2024-02-01

89
papers

2,045
citations

257450

24
h-index

265206

42
g-index

91
all docs

91
docs citations

91
times ranked

3603
citing authors

#	ARTICLE	IF	CITATIONS
1	Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, , 1-2.	3.0	0
2	The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience. <i>European Journal of Haematology</i> , 2021, 106, 340-345.	2.2	5
3	Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 675-678.	0.6	2
4	Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 182-188.	3.0	4
5	N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution. <i>Annals of Hematology</i> , 2021, 100, 2521-2527.	1.8	3
6	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
7	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 394-399.	0.4	11
8	High incidence of <i>Pneumocystis jirovecii</i> pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era. <i>Cytotherapy</i> , 2020, 22, 27-34.	0.7	18
9	Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1463-1473.	1.6	32
10	Anti-myeloma potential of ruxolitinib in co-existing JAK2V617F positive smouldering myeloma and polycythaemia vera. <i>British Journal of Haematology</i> , 2020, 189, e114-e118.	2.5	2
11	Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables. <i>Bone Marrow Transplantation</i> , 2019, 54, 368-382.	2.4	11
12	Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019007.	1.3	5
13	Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis – Part II: Non-kidney transplant. <i>Clinical Transplantation</i> , 2019, 33, e13625.	1.6	14
14	Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center. <i>Leukemia and Lymphoma</i> , 2019, 60, 3199-3203.	1.3	9
15	Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2019, 33, e13560.	1.6	11
16	Cutaneous plasmacytoma-like posttransplant lymphoproliferative disorder after renal transplantation with response to imiquimod 5% cream and reduced immunosuppression. <i>JAAD Case Reports</i> , 2019, 5, 1071-1074.	0.8	3
17	Red cell transfusion thresholds in haematopoietic stem cell transplantation. <i>ISBT Science Series</i> , 2019, 14, 123-128.	1.1	1
18	Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. <i>Leukemia and Lymphoma</i> , 2019, 60, 1275-1282.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. <i>Blood Cancer Journal</i> , 2018, 8, 14.	6.2	3
20	Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. <i>Leukemia</i> , 2018, 32, 986-995.	7.2	60
21	Network geometry of evidence from randomised controlled trials addressing donor selection and source of haematopoietic progenitor cells used in allogeneic transplantation: a systematic scoping review. <i>Transfusion Medicine</i> , 2018, 28, 371-379.	1.1	0
22	Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e69-e75.	0.4	6
23	Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. <i>Leukemia and Lymphoma</i> , 2018, 59, 1920-1926.	1.3	13
24	Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis. <i>Transfusion</i> , 2018, 58, 2437-2452.	1.6	17
25	Economics of Multiple Myeloma. <i>Blood</i> , 2018, 132, 4773-4773.	1.4	4
26	The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study. <i>Blood</i> , 2018, 132, 4788-4788.	1.4	1
27	Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing. <i>Blood</i> , 2018, 132, 4459-4459.	1.4	2
28	Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients. <i>Blood</i> , 2018, 132, 242-242.	1.4	13
29	Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns. <i>Blood</i> , 2018, 132, 4496-4496.	1.4	0
30	Monoclonal Gammopathy of Clinical Significance - a Single Center Experience. <i>Blood</i> , 2018, 132, 4495-4495.	1.4	0
31	Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 431-439.	1.8	25
32	A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers. <i>Transplant Infectious Disease</i> , 2017, 19, e12706.	1.7	9
33	Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?. <i>Bone Marrow Transplantation</i> , 2017, 52, 915-917.	2.4	13
34	Balancing give and take between patients and their spousal caregivers in hematopoietic stem cell transplantation. <i>Psycho-Oncology</i> , 2017, 26, 2224-2231.	2.3	7
35	Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. <i>JAMA Neurology</i> , 2016, 73, 652.	9.0	71
36	Acquired Factor XIII Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case Series. <i>Transfusion Medicine Reviews</i> , 2016, 30, 123-131.	2.0	21

#	ARTICLE	IF	CITATIONS
37	Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials. <i>Transfusion</i> , 2016, 56, 2607-2614.	1.6	10
38	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
39	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016, 127, 3082-3091.	1.4	83
40	Revised International Staging System Applied to Real World Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 511-518.	0.4	37
41	Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study. <i>BMJ Open</i> , 2016, 6, e013483.	1.9	6
42	Improved Prediction of CD34 + Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 763-767.	2.0	6
43	Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds. <i>Blood</i> , 2016, 128, 1032-1032.	1.4	22
44	Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review. <i>Cancer Medicine</i> , 2015, 4, 1817-1827.	2.8	2
45	Clinical outcomes of immunoglobulin use in solid organ transplant recipients: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2015, 4, 167.	5.3	8
46	Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation. <i>Transfusion</i> , 2015, 55, 253-258.	1.6	14
47	Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation. <i>BMJ Open</i> , 2015, 5, e008316.	1.9	12
48	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33
49	Current Trends in Clinical Studies of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 364-370.	2.0	3
50	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1513-1518.	2.4	34
51	A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 135-140.	1.3	6
52	A Systematic Review of Preclinical Studies on the Therapeutic Potential of Mesenchymal Stromal Cell-Derived Microvesicles. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 150-160.	5.6	248
53	Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Heavy Chain (HLC) Normalization. <i>Blood</i> , 2015, 126, 1982-1982.	1.4	0
54	A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program. <i>Bone Marrow Transplantation</i> , 2014, 49, 751-755.	2.4	17

#	ARTICLE	IF	CITATIONS
55	Autologous Stem Cell Transplantation for Stiff Person Syndrome. <i>JAMA Neurology</i> , 2014, 71, 1296.	9.0	29
56	Transplantation of Umbilical Cord Blood–Derived Cells for Novel Indications in Regenerative Therapy or Immune Modulation: A Scoping Review of Clinical Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 20-25.	2.0	38
57	Impact of ethnicity on human umbilical cord blood banking: a systematic review. <i>Transfusion</i> , 2014, 54, 2122-2127.	1.6	15
58	Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2712-2720.	1.3	9
59	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
60	Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation: Practical Approach to Imaging Diagnosis. <i>Radiographics</i> , 2014, 34, 663-683.	3.3	42
61	A Canadian Cost Analysis Comparing the Use of Bortezomib or Lenalidomide as Maintenance Therapies in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. <i>Value in Health</i> , 2014, 17, A77.	0.3	1
62	Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. <i>Blood</i> , 2014, 124, 38-38.	1.4	15
63	First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity. <i>Blood</i> , 2014, 124, 3990-3990.	1.4	0
64	Identification and Management of Glucocorticoid-Induced Hyperglycemia on an Inpatient Malignant Hematology Ward: A Quality Improvement Initiative. <i>Blood</i> , 2014, 124, 6004-6004.	1.4	0
65	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
66	Is Cytomegalovirus Testing of Blood Products Still Needed for Hematopoietic Stem Cell Transplant Recipients in the Era of Universal Leukoreduction?. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1719-1724.	2.0	39
67	Major ABO-incompatible BMT: isohemagglutinin reduction with plasma exchange is safe and avoids graft manipulation. <i>Bone Marrow Transplantation</i> , 2013, 48, 953-957.	2.4	9
68	Donor selection for patients undergoing allogeneic hematopoietic SCT: assessment of the priorities of Canadian hematopoietic SCT physicians. <i>Bone Marrow Transplantation</i> , 2013, 48, 314-316.	2.4	4
69	Rh D alloimmunization in allogeneic HSCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 459-460.	2.4	7
70	The Influence of Social Support on Hematopoietic Stem Cell Transplantation Survival: A Systematic Review of Literature. <i>PLoS ONE</i> , 2013, 8, e61586.	2.5	43
71	The Impact of Prolonged Storage of Red Blood Cells on Cancer Survival. <i>PLoS ONE</i> , 2013, 8, e68820.	2.5	18
72	Serial assessment of toxicity after hematopoietic SCT can discern kinetics of transplant-related organ injury and patterns of recovery. <i>Bone Marrow Transplantation</i> , 2012, 47, 1375-1376.	2.4	1

#	ARTICLE	IF	CITATIONS
73	Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patients. <i>Thrombosis Research</i> , 2012, 130, 323-326.	1.7	89
74	Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1191-1203.	2.0	69
75	Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation. <i>Transfusion</i> , 2012, 52, 2049-2054.	1.6	9
76	The Use of Intravenous Antibiotics at the Onset of Neutropenia in Patients Receiving Outpatient-Based Hematopoietic Stem Cell Transplants. <i>PLoS ONE</i> , 2012, 7, e46220.	2.5	6
77	The Influence of the Duration of Storage of Red Blood Cells On Cancer Survival. <i>Blood</i> , 2012, 120, 1184-1184.	1.4	0
78	Storage time of transfused red blood cells and impact on clinical outcomes in hematopoietic stem cell transplantation. <i>Transfusion</i> , 2011, 51, 2488-2494.	1.6	17
79	Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 653-663.	3.8	164
80	Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 207.	1.6	25
81	Retrospective Review of Invasive Fungal Disease in a Cohort of Patients with Acute Leukemia. <i>Blood</i> , 2011, 118, 4265-4265.	1.4	7
82	Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies,. <i>Blood</i> , 2011, 118, 4046-4046.	1.4	0
83	Thromboprophylaxis In Multiple Myeloma Patients Undergoing Immunomodulatory Therapy with Thalidomide and Lenalidomide: A Systematic Review and Meta-Analysis.. <i>Blood</i> , 2010, 116, 1090-1090.	1.4	2
84	Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation. <i>Transfusion</i> , 2008, 48, 2421-2428.	1.6	11
85	Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1039-1044.	2.0	53
86	Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Venoo-occlusive Disease in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 206-217.	2.0	111
87	Observational studies: what is a cohort study?. <i>Transfusion</i> , 2007, 47, 1115-1117.	1.6	3
88	Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2552-2554.	3.8	35
89	Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada. <i>Leukemia and Lymphoma</i> , 0, , 1-8.	1.3	1